Amino or acylamino-substituted pyrimidinyl cephalosporanic acid derivatives and pharmaceutical compositions thereof

Claim 2

A compound of the formula: ##STR14## wherein R 1 is a group of the formula ##STR15## in which R a 1 is amino or acylamino located at the 2, 4 or 6-position of the ring, acyl being selected from the group consisting of lower alkanoyl, halo (lower) alkanoyl, and lower alkoxycarbonyl, R b 1 and R c 1 are each hydrogen, halogen, lower alkoxy, phenylthio, tolylthio, xylylthio, mesitylthio or naphthylthio, R 2 is hydrogen or lower alkoxy R 4 is substituted or unsubstituted heterocyclic-thiomethyl, the heterocyclic moiety of R 4 being a 5 to 6-membered monocyclic group or an unsaturated bicyclic condensed heterocyclic group whose rings have 5 or 6 members, the ring atoms of said heterocyclic group being C and at least one hetero atom selected from N, O and S, the heterocyclic to thiomethyl bond being a C--S bond, the substituent in said substituted heterocyclicthiomethyl group being located in the heterocyclic moiety, and being selected from lower alkyl, C 5-6 cycloalkyl, lower alkenyl, amino(lower) alkyl, lower alkoxy-carbonyl amino (lower) alkyl, carboxy (lower) alkyl, sulfo (lower) alkyl, phenyl, mono to tri halo substituted phenyl, and lower alkyl amino (lower) alkyl, R 6 is hydrogen, lower alkyl, mono to tri halo (lower) alkyl, lower alkenyl, lower alkynyl, phenyl, tolyl, xylyl, cumenyl, naphthyl, phenyl (lower) alkyl, mono or di halo (lower) alkanoyl, or lower alkoxy, and R 5 is carboxy, or pharmaceutically acceptable esterified carboxy, and non-toxic pharmaceutically acceptable salts thereof.

Claim 3

A compound of claim 1, wherein R 1 is a group of the formula: ##STR16## in which R a 1 is amino or acylamino, located at the 2, 4 or 6 position of the ring, acyl being selected from the group consisting of lower alkanoyl, halo (lower) alkanoyl, and lower alkoxycarbonyl, R b 1 and R c 1 are each hydrogen, halogen, lower alkoxy or phenylthio, R 2 is hydrogen or lower alkoxy, and R 4 is substituted or unsubstituted unsaturated 5 to 6 -membered heterocyclic-thiomethyl the ring atoms of which are 2 or 3 carbon atoms, two nitrogen atoms and one sulfur atom, and the substituent of which is selected from the group consisting of lower alkyl, amino(lower) alkyl and lower alkoxycarbonylamino (lower) alkyl, substituted or unsubstituted unsaturated 5 to 6-membered heterocyclicthiomethyl the ring atoms of which are 2 or 3 carbon atoms, two nitrogen atoms and one oxygen atom and the substituent of which is halophenyl, substituted or unsubstituted unsaturated 5 to 6-membered heterocyclic-thiomethyl, the ring atoms of which are 1 or 2 carbon atoms and four nitrogen atoms and the subsittuent of which is selected from the group consisting of lower alkyl, carboxy (lower) alkyl, lower alkenyl, amino (lower) alkyl and lower alkoxycarbonylamino(lower)alkyl, unsaturated 5 to 6-membered heterocyclicthiomethyl the ring atoms of which are 3 or 4 carbon atoms and two nitrogen atoms or tetrazolopyridazinylthiomethyl, R 5 is carboxy or a pharmaceutically acceptable esterified carboxy group, and R 6 is hydrogen, lower alkyl, trihalo(lower)alkyl, lower alkenyl, lower alkynyl, phenyl or phenyl(lower)alkyl.

Claim 4

A compound of claim 2, wherein R 1 is a group of the formula: ##STR17## in which R a 1 is amino, lower alkanoyl amino or trihalo(lower) alkanoyl amino, located at the 2, 4 or 6 position of the ring R b 1 and R c 1 are each hydrogen, halogen, lower alkoxy or phenylthio, and R 2 is hydrogen or lower alkoxy, R 4 is thiadiazolylthiomethyl which is unsubstituted or substituted by a substituent selected from the group consisting of lower alkyl, amino(lower)alkyl and lower alkoxycarbonylamino(lower)alkyl, halophenyloxadiazolylthiomethyl, tetrazolylthiomethyl which is unsubstituted or substituted by a substituent selected from the groups consisting of lower alkyl, carboxy(lower)alkyl, lower alkenyl, amino(lower alkyl) and lower alkoxycarbonylamino(lower)alkyl, pyrazinylthiomethyl or tetrazolopyridazinylthiomethyl, R 5 is carboxy, nitrophenyl(lower)alkoxycarbonyl or diphenyl(lower)alkoxycarbonyl, and R 6 is hydrogen, lower alkyl, trihalo(lower)alkyl, lower alkenyl, lower alkynyl, phenyl or phenyl(lower)alkyl.

Claim 5

A compound of claim 3, wherein R 1 is a group of the formula: ##STR18## in which R c 1 is hydrogen, halogen, lower alkoxy or phenylthio and R 2 is hydrogen.

Claim 6

A compound of claim 4, wherein R 5 is carboxy.

Claim 7

A compound of claim 5, wherein R c 1 is hydrogen, chloro, methoxy or phenylthio, R 4 is 1,3,4-thiadiazol-2-ylthiomethyl, 5-methyl-1,3,4-thiadiazol-2-ylthiomethyl, 5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthiomethyl, 1-methyl-1H-tetrazol-5-ylthiomethyl, 1-allyl-1H-tetrazol-5-ylthiomethyl, 2-pyrazinylthiomethyl, tetrazolo[1,5-b]pyridazin-6-ylthiomethyl, or 1-(2-aminoethyl)-1H-tetrazol-5-ylthiomethyl and R 6 is a methyl, ethyl, propyl, allyl, benzyl or phenyl.

Claim 8

A compound of claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-methoxyiminoacetamido]-3-(1,3,4-thiadiazol-2-yl)thiomethyl-3-cephem-4-carboxylic acid (syn isomer).

Claim 9

A compound of claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-ethoxyiminoacetamido]-3-(1,3,4-thiadiazol-2-yl)thiomethyl-3-cephem-4-carboxylic acid (syn isomer).

Claim 10

A compound of claim 6, which is 7-[2-(4-aminopyridin-2-yl)-2-propoxyiminoacetamido]-3-(1,3,4-thiadiazol-2-yl)thiomethyl-3-cephem-4-carboxylic acid (syn isomer).

Claim 11

A compound of claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-allyloxyiminoacetamido]-3-(1,3,4-thiadiazol-2-yl)thiomethyl-3-cephem-4-carboxylic acid (syn isomer).

Claim 12

A compound of claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-methoxyiminoacetamido]-3-(5-methyl-1,3,4-thiadiazol-2-yl)-thiomethyl-3-cephem-4-carboxylic acid (syn isomer).

Claim 13

A compound of claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-methoxyiminoacetamido]-3-(1-methyl-1H-tetrazol-b 5-yl)thiomethyl-3-cephem-4-carboxylic acid (syn isomer).

Claim 14

A compound of claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-methoxyiminoacetamido]-3-(1-allyl-1H-tetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid (syn isomer).

Claim 15

A compound of claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-methoxyiminoacetamido]-3-(tetrazolo[1,5-b]pyridazin-6-yl)-thiomethyl-3-cephem-4-carboxylic acid (syn isomer).

Claim 16

A compound of claim 3 wherein R 1 is a group of the formula: ##STR19## in which R c 1 is hydrogen or halogen, R 2 is hydrogen, R 4 is tetrazolylthiomethyl having a lower alkyl, R 5 is carboxy and R 6 is lower alkyl.

Claim 17

A compond of claim 15, wherein R c 1 is hydrogen or chloro, R 4 is 1-methyl-1H-tetrazol-5-ylthiomethyl and R 6 is methyl.

Claim 18

A compound of claim 3, wherein R 1 is a group of the formula: ##STR20## in which R a 1 is lower alkanoylamino, and R 2 is hydrogen.

Claim 19

A compound of claim 17, wherein R a 1 is formamido, R 4 is, 1,3,4-thiadiazol-2-ylthiomethyl, 1-methyl-1H-tetrazol-5-ylthiomethyl or tetrazolo[1,5-b]pyridazin-6-yl thiomethyl R 5 is carboxy and R 6 is methyl, ethyl, propyl, allyl or benzyl.

Claim 20

A compound of claim 3, wherein R 1 is a group of the formula: ##STR21## in which R a 1 is lower alkanoylamino and R c 1 is hydrogen or halogen,and R 2 is hydrogen.

Claim 21

A compound of claim 19, wherein R a 1 is formamido, R c 1 is hydrogen or chloro, R 4 is 1-methyl-1H-tetrazol-5-ylthiomethyl, R 5 is carboxy and R 6 is methyl.

Claim 22

A compound according to claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-methoxyiminoacetamido]-3-[1-(2-aminoethyl)-1H-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid (syn isomer).

Claim 23

A compound according to claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-phenoxyiminoacetamido]-3-[1-(2-aminoethyl)-1H-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid (syn isomer).

Claim 24

A compound according to claim 6, which is 7-[2-(4-aminopyrimidin-2-yl)-2-phenoxyiminoacetamido]-3-(1,3,4-thiadiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acid (syn isomer).

Claim 25

A pharmaceutical antibacterial composition comprising, as an active ingredient, the compound of claim 1 in association with a non-toxic, pharmaceutically acceptable carrier or excipient.

Claim 26

A method for treating an infectious disease caused by pathogens, which comprises internally administering the compound of claim 1 to infected human beings.